New Launch19 Aug 2025, 09:53 am
Glenmark Pharmaceuticals Inc., USA to Launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial
AI Summary
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the upcoming launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) in September 2025. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine® for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. The Mycamine® for Injection market achieved annual sales of approximately $60.7 million as per IQVIA® sales data for the 12-month period ending June 2025. Glenmark's product is only approved for the indications listed in Glenmark’s approved label.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)
- Product is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine® for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc.
- Mycamine® for Injection market achieved annual sales of approximately $60.7 million as per IQVIA® sales data for the 12-month period ending June 2025
- Glenmark's product is only approved for the indications listed in Glenmark’s approved label